Non‐Hydroxamate Inhibitors of IspC Enzyme in the MEP Pathway: Structural Insights and Drug Development Potential
Chemical Biology and Drug Design
MARCH 18, 2025
The review provides a comprehensive analysis of non-hydroxamate inhibitors for IspC, an enzyme crucial in the MEP pathway, highlighting its structural diversity and improved drug development potential. This has led to increased interest in non-hydroxamate inhibitors.
Let's personalize your content